News | Heart Failure | March 29, 2022

Eko Launches Screening Solution to Help Catch Heart Disease Early

FDA-cleared artificial intelligence (AI) algorithms that detect leading indicators of heart disease are now available to healthcare professionals in the all-new Eko App 

Eko, a digital health company advancing heart and lung disease detection, has announced the launch of its newly-redesigned Eko App, which will transform patient interactions into an opportunity to screen for cardiovascular disease.

March 29, 2022 – Eko, a digital health company advancing heart and lung disease detection, has announced the launch of its newly-redesigned Eko App, which will transform patient interactions into an opportunity to screen for cardiovascular disease. Heart disease is the leading cause of death in the U.S., and there has not been an efficient and affordable solution to screen for heart disease at the physical exam until now.

"Current clinical workflows for detecting heart disease often include expensive tests performed by a specialist in an emergency setting, which makes early diagnosis nearly impossible," said Dr. Adam Saltman, Chief Medical Officer, Eko. "The physical exam offers an opportunity for early detection of heart disease. However, as many as 80% of abnormal heart sounds go unrecognized when exams are performed with a traditional stethoscope. This can delay life-saving treatments for patients."

Eko has transformed the traditional stethoscope into an intelligent disease detection tool to help clinicians spot cardiovascular disease easier during the physical exam. Their line of smart stethoscopes, when paired with its accompanying automated disease detection software using the Eko App, analyzes heart sounds with FDA-cleared and clinically proven AI algorithms.* In seconds, the algorithms can detect heart murmurs and atrial fibrillation (AFib)** with comparable performance to human experts.    

"Frontline healthcare professionals are our best line of defense in catching cardiovascular disease early on, but they are challenged to do so by outdated tools, insufficient time, and inadequate resources," said Connor Landgraf, CEO and Co-founder, Eko. "With a disease that is so pervasive in our society, it is imperative that we provide every healthcare professional with a solution that helps them diagnose with more confidence and give their patients the best care possible. This is how we'll save millions of lives in the coming years."

Eko's AI algorithm to identify heart murmurs, a leading indicator of heart valve disease, was clinically validated to perform at a sensitivity of 87.6% and specificity of 87.8%. Their algorithm for detecting atrial fibrillation performed at a sensitivity of 98.9% and a specificity of 96.9%. Real-world validation of Eko's heart murmur detection algorithm came from a recent, peer-reviewed publication in the Journal of the American Heart Association. It was the largest study on AI analysis of cardiac murmurs to date.

"Eko's technology has given me the added assurance to detect and verify heart murmurs and atrial fibrillation in my patients," said Joanna Kmiecik, MD, Family Medicine Specialist. "The ease-of-use and portable nature of Eko's products helps me to examine patients right in my office, with minimal impact to my physical examination routine. If I hear a heart sound suspicious of disease, Eko accurately confirms it in seconds. This helps me to determine care decisions and refer to a specialist confidently when appropriate. My patients even enjoy how they can engage with the app, and I feel I am a better clinician." 

For more information: https://www.ekohealth.com/

*For healthcare professional use only
**Atrial fibrillation detection only available when Eko App is used with Eko DUO ECG + Digital Stethoscope

 

Related Digital Health Content:

How Advances in Wearable Cardiac Monitors Improve the Patient and Clinician Experience

Longer Continuous Ambulatory Cardiac Monitoring Enables More Comprehensive Evaluation of Atrial Fibrillation

Cardea Solo Wearable ECG Collects High-altitude Cardiac Data on Denali Expedition

Cardiac Insight Partners With VivoSense for Cardiovascular Research

Wearable Cardiac Monitors Are Effective for Tracking Atrial Fibrillation Following Ablation

As Interpretation Criteria Evolve, False Positive Athlete ECG Screening Rates Can Decrease


Related Content

News | Wearables

August 31, 2022 — Medtronic plc, a global leader in healthcare technology, announced it has entered into a strategic ...

Home August 31, 2022
Home
News | Wearables

August 24, 2022 — Screening individuals for atrial fibrillation (AF) using wearable devices is more cost-effective than ...

Home August 24, 2022
Home
News | Wearables

July 25, 2022 — iRhythm Technologies, Inc., a leading digital healthcare solutions company focused on the advancement of ...

Home July 25, 2022
Home
News | Wearables

May 18, 2022 — A new app developed by the Mayo Clinic transmits Apple Watch electrocardiograms (ECG) signals recorded in ...

Home May 18, 2022
Home
News | Wearables

May 4, 2022 – Single-lead ECG tracings from an Apple Watch interpreted by an artificial intelligence (AI) algorithm ...

Home May 04, 2022
Home
News | Wearables

April 14, 2022 – Atrial fibrillation (AFib) was confirmed in nearly 94% of people who were initially identified to have ...

Home April 14, 2022
Home
News | Wearables

April 12, 2022 — Fitbit received clearance from the U.S. Food and Drug Administration for its new PPG ...

Home April 12, 2022
Home
News | Wearables
March 25, 2022 – Consumers are increasingly using smartwatches and other wearable devices to measure their heart rate ...
Home March 25, 2022
Home
News | Wearables
March 1, 2022 – A new report says the wearable healthcare devices market is anticipated to grow at a CAGR of 13% from ...
Home March 01, 2022
Home
News | Wearables

Chenyang Lu, a professor of computer science and engineering, is marrying Fitbits with machine learning to predict which ...

Home February 09, 2022
Home
Subscribe Now